Surgical and Oncological Outcomes of Salvage Hepatectomy for Locally Recurrent Hepatocellular Carcinoma after Locoregional Therapy: A Single-Institution Experience
Surgical and oncological outcomes of hepatectomy for recurrent hepatocellular carcinoma (HCC) after locoregional therapy, including locally recurrent HCC (LR-HCC), were examined. Among 273 consecutive patients who underwent hepatectomy for HCC, 102 with recurrent HCC were included and retrospectivel...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-04, Vol.15 (8), p.2320 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 2320 |
| container_title | Cancers |
| container_volume | 15 |
| creator | Minagawa, Takuya Itano, Osamu Kitago, Minoru Abe, Yuta Yagi, Hiroshi Hibi, Taizo Shinoda, Masahiro Ojima, Hidenori Sakamoto, Michiie Kitagawa, Yuko |
| description | Surgical and oncological outcomes of hepatectomy for recurrent hepatocellular carcinoma (HCC) after locoregional therapy, including locally recurrent HCC (LR-HCC), were examined. Among 273 consecutive patients who underwent hepatectomy for HCC, 102 with recurrent HCC were included and retrospectively reviewed. There were 35 patients with recurrent HCC after primary hepatectomy and 67 with recurrent HCC after locoregional therapies. Pathologic review revealed 30 patients with LR-HCC. Background liver function was significantly worse in patients with recurrent HCC after locoregional therapy (
= 0.002). AFP (
= 0.031) and AFP-L3 (
= 0.033) serum levels were significantly higher in patients with LR-HCC. Perioperative morbidities were significantly more frequently observed with recurrent HCC after locoregional therapies (
= 0.048). Long-term outcomes of recurrent HCC after locoregional therapies were worse than those after hepatectomy, though there was no prognostic difference according to the recurrence patterns after locoregional therapies. Multivariate analyses showed that prognostic factors for resected recurrent HCC were previous locoregional therapy (hazard ratio [HR] 2.0;
= 0.005), multiple HCCs (HR 2.8;
< 0.001), and portal venous invasion (HR 2.3;
= 0.001). LR-HCC was not a prognostic factor. In conclusion, salvage hepatectomy for LR-HCC showed worse surgical outcomes but a favorable prognosis. |
| doi_str_mv | 10.3390/cancers15082320 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10137253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A747309029</galeid><sourcerecordid>A747309029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-7e4006f9a5f22c22296079b84eae702104543a35983f666e9b4d5951632699db3</originalsourceid><addsrcrecordid>eNptkk1v3CAQhq2qVROlOfdWIfXSixMMGEwv1WqVNpFWWqmbnhGLxw4RBhfsKPt7-kfLdtM0iQoHvp73Hc0wRfG-wmeUSnxutDcQU1XjhlCCXxXHBAtSci7Z6yf7o-I0pVucB6WV4OJtcURFJTFhzXHxazPH3hrtkPYtWnsTXDic1_NkwgAJhQ5ttLvTPaBLGPUEZgrDDnUholXIpNuh72DmGMFPByIYcG52OqKljsb6MGikuwn-CEKE3gafI1zfQNTj7jNaoI31vYPyyqfJTvOU39HF_QjRQk7xXfGm0y7B6cN6Uvz4enG9vCxX629Xy8WqNIzRqRTAMOad1HVHiCGESI6F3DYMNAhMKsxqRjWtZUM7zjnILWtrWVecEi5lu6UnxZeD7zhvB2hNzidqp8ZoBx13Kmirnr94e6P6cKcqXFFBapodPj04xPBzhjSpwaZ9MbSHMCdFmorVRFCKM_rxBXob5pjLsqcwr7EUVPyjeu1AWd-FHNjsTdVCMEFx_kaZqbP_UHm2MFgTPHQ23z8TnB8EJoaUInSPSVZY7XtLveitrPjwtDaP_N9Oor8Bhc3MVQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2806509737</pqid></control><display><type>article</type><title>Surgical and Oncological Outcomes of Salvage Hepatectomy for Locally Recurrent Hepatocellular Carcinoma after Locoregional Therapy: A Single-Institution Experience</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Minagawa, Takuya ; Itano, Osamu ; Kitago, Minoru ; Abe, Yuta ; Yagi, Hiroshi ; Hibi, Taizo ; Shinoda, Masahiro ; Ojima, Hidenori ; Sakamoto, Michiie ; Kitagawa, Yuko</creator><creatorcontrib>Minagawa, Takuya ; Itano, Osamu ; Kitago, Minoru ; Abe, Yuta ; Yagi, Hiroshi ; Hibi, Taizo ; Shinoda, Masahiro ; Ojima, Hidenori ; Sakamoto, Michiie ; Kitagawa, Yuko</creatorcontrib><description>Surgical and oncological outcomes of hepatectomy for recurrent hepatocellular carcinoma (HCC) after locoregional therapy, including locally recurrent HCC (LR-HCC), were examined. Among 273 consecutive patients who underwent hepatectomy for HCC, 102 with recurrent HCC were included and retrospectively reviewed. There were 35 patients with recurrent HCC after primary hepatectomy and 67 with recurrent HCC after locoregional therapies. Pathologic review revealed 30 patients with LR-HCC. Background liver function was significantly worse in patients with recurrent HCC after locoregional therapy (
= 0.002). AFP (
= 0.031) and AFP-L3 (
= 0.033) serum levels were significantly higher in patients with LR-HCC. Perioperative morbidities were significantly more frequently observed with recurrent HCC after locoregional therapies (
= 0.048). Long-term outcomes of recurrent HCC after locoregional therapies were worse than those after hepatectomy, though there was no prognostic difference according to the recurrence patterns after locoregional therapies. Multivariate analyses showed that prognostic factors for resected recurrent HCC were previous locoregional therapy (hazard ratio [HR] 2.0;
= 0.005), multiple HCCs (HR 2.8;
< 0.001), and portal venous invasion (HR 2.3;
= 0.001). LR-HCC was not a prognostic factor. In conclusion, salvage hepatectomy for LR-HCC showed worse surgical outcomes but a favorable prognosis.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15082320</identifier><identifier>PMID: 37190248</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Alpha fetoproteins ; Biomarkers ; Cancer ; Care and treatment ; Chemotherapy ; Hepatectomy ; Hepatocellular carcinoma ; Hepatoma ; Liver ; Liver cancer ; Medical colleges ; Medical prognosis ; Methods ; Patient outcomes ; Patients ; Prognosis ; Serum levels ; Surgeons ; Surgery ; Surgical outcomes ; Tumors</subject><ispartof>Cancers, 2023-04, Vol.15 (8), p.2320</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c443t-7e4006f9a5f22c22296079b84eae702104543a35983f666e9b4d5951632699db3</cites><orcidid>0000-0001-9154-246X ; 0000-0002-6867-228X ; 0000-0002-2197-9508</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137253/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137253/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37190248$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Minagawa, Takuya</creatorcontrib><creatorcontrib>Itano, Osamu</creatorcontrib><creatorcontrib>Kitago, Minoru</creatorcontrib><creatorcontrib>Abe, Yuta</creatorcontrib><creatorcontrib>Yagi, Hiroshi</creatorcontrib><creatorcontrib>Hibi, Taizo</creatorcontrib><creatorcontrib>Shinoda, Masahiro</creatorcontrib><creatorcontrib>Ojima, Hidenori</creatorcontrib><creatorcontrib>Sakamoto, Michiie</creatorcontrib><creatorcontrib>Kitagawa, Yuko</creatorcontrib><title>Surgical and Oncological Outcomes of Salvage Hepatectomy for Locally Recurrent Hepatocellular Carcinoma after Locoregional Therapy: A Single-Institution Experience</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Surgical and oncological outcomes of hepatectomy for recurrent hepatocellular carcinoma (HCC) after locoregional therapy, including locally recurrent HCC (LR-HCC), were examined. Among 273 consecutive patients who underwent hepatectomy for HCC, 102 with recurrent HCC were included and retrospectively reviewed. There were 35 patients with recurrent HCC after primary hepatectomy and 67 with recurrent HCC after locoregional therapies. Pathologic review revealed 30 patients with LR-HCC. Background liver function was significantly worse in patients with recurrent HCC after locoregional therapy (
= 0.002). AFP (
= 0.031) and AFP-L3 (
= 0.033) serum levels were significantly higher in patients with LR-HCC. Perioperative morbidities were significantly more frequently observed with recurrent HCC after locoregional therapies (
= 0.048). Long-term outcomes of recurrent HCC after locoregional therapies were worse than those after hepatectomy, though there was no prognostic difference according to the recurrence patterns after locoregional therapies. Multivariate analyses showed that prognostic factors for resected recurrent HCC were previous locoregional therapy (hazard ratio [HR] 2.0;
= 0.005), multiple HCCs (HR 2.8;
< 0.001), and portal venous invasion (HR 2.3;
= 0.001). LR-HCC was not a prognostic factor. In conclusion, salvage hepatectomy for LR-HCC showed worse surgical outcomes but a favorable prognosis.</description><subject>Alpha fetoproteins</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Hepatectomy</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Medical colleges</subject><subject>Medical prognosis</subject><subject>Methods</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Serum levels</subject><subject>Surgeons</subject><subject>Surgery</subject><subject>Surgical outcomes</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1v3CAQhq2qVROlOfdWIfXSixMMGEwv1WqVNpFWWqmbnhGLxw4RBhfsKPt7-kfLdtM0iQoHvp73Hc0wRfG-wmeUSnxutDcQU1XjhlCCXxXHBAtSci7Z6yf7o-I0pVucB6WV4OJtcURFJTFhzXHxazPH3hrtkPYtWnsTXDic1_NkwgAJhQ5ttLvTPaBLGPUEZgrDDnUholXIpNuh72DmGMFPByIYcG52OqKljsb6MGikuwn-CEKE3gafI1zfQNTj7jNaoI31vYPyyqfJTvOU39HF_QjRQk7xXfGm0y7B6cN6Uvz4enG9vCxX629Xy8WqNIzRqRTAMOad1HVHiCGESI6F3DYMNAhMKsxqRjWtZUM7zjnILWtrWVecEi5lu6UnxZeD7zhvB2hNzidqp8ZoBx13Kmirnr94e6P6cKcqXFFBapodPj04xPBzhjSpwaZ9MbSHMCdFmorVRFCKM_rxBXob5pjLsqcwr7EUVPyjeu1AWd-FHNjsTdVCMEFx_kaZqbP_UHm2MFgTPHQ23z8TnB8EJoaUInSPSVZY7XtLveitrPjwtDaP_N9Oor8Bhc3MVQ</recordid><startdate>20230416</startdate><enddate>20230416</enddate><creator>Minagawa, Takuya</creator><creator>Itano, Osamu</creator><creator>Kitago, Minoru</creator><creator>Abe, Yuta</creator><creator>Yagi, Hiroshi</creator><creator>Hibi, Taizo</creator><creator>Shinoda, Masahiro</creator><creator>Ojima, Hidenori</creator><creator>Sakamoto, Michiie</creator><creator>Kitagawa, Yuko</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9154-246X</orcidid><orcidid>https://orcid.org/0000-0002-6867-228X</orcidid><orcidid>https://orcid.org/0000-0002-2197-9508</orcidid></search><sort><creationdate>20230416</creationdate><title>Surgical and Oncological Outcomes of Salvage Hepatectomy for Locally Recurrent Hepatocellular Carcinoma after Locoregional Therapy: A Single-Institution Experience</title><author>Minagawa, Takuya ; Itano, Osamu ; Kitago, Minoru ; Abe, Yuta ; Yagi, Hiroshi ; Hibi, Taizo ; Shinoda, Masahiro ; Ojima, Hidenori ; Sakamoto, Michiie ; Kitagawa, Yuko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-7e4006f9a5f22c22296079b84eae702104543a35983f666e9b4d5951632699db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Alpha fetoproteins</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Hepatectomy</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Medical colleges</topic><topic>Medical prognosis</topic><topic>Methods</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Serum levels</topic><topic>Surgeons</topic><topic>Surgery</topic><topic>Surgical outcomes</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Minagawa, Takuya</creatorcontrib><creatorcontrib>Itano, Osamu</creatorcontrib><creatorcontrib>Kitago, Minoru</creatorcontrib><creatorcontrib>Abe, Yuta</creatorcontrib><creatorcontrib>Yagi, Hiroshi</creatorcontrib><creatorcontrib>Hibi, Taizo</creatorcontrib><creatorcontrib>Shinoda, Masahiro</creatorcontrib><creatorcontrib>Ojima, Hidenori</creatorcontrib><creatorcontrib>Sakamoto, Michiie</creatorcontrib><creatorcontrib>Kitagawa, Yuko</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Minagawa, Takuya</au><au>Itano, Osamu</au><au>Kitago, Minoru</au><au>Abe, Yuta</au><au>Yagi, Hiroshi</au><au>Hibi, Taizo</au><au>Shinoda, Masahiro</au><au>Ojima, Hidenori</au><au>Sakamoto, Michiie</au><au>Kitagawa, Yuko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Surgical and Oncological Outcomes of Salvage Hepatectomy for Locally Recurrent Hepatocellular Carcinoma after Locoregional Therapy: A Single-Institution Experience</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-04-16</date><risdate>2023</risdate><volume>15</volume><issue>8</issue><spage>2320</spage><pages>2320-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Surgical and oncological outcomes of hepatectomy for recurrent hepatocellular carcinoma (HCC) after locoregional therapy, including locally recurrent HCC (LR-HCC), were examined. Among 273 consecutive patients who underwent hepatectomy for HCC, 102 with recurrent HCC were included and retrospectively reviewed. There were 35 patients with recurrent HCC after primary hepatectomy and 67 with recurrent HCC after locoregional therapies. Pathologic review revealed 30 patients with LR-HCC. Background liver function was significantly worse in patients with recurrent HCC after locoregional therapy (
= 0.002). AFP (
= 0.031) and AFP-L3 (
= 0.033) serum levels were significantly higher in patients with LR-HCC. Perioperative morbidities were significantly more frequently observed with recurrent HCC after locoregional therapies (
= 0.048). Long-term outcomes of recurrent HCC after locoregional therapies were worse than those after hepatectomy, though there was no prognostic difference according to the recurrence patterns after locoregional therapies. Multivariate analyses showed that prognostic factors for resected recurrent HCC were previous locoregional therapy (hazard ratio [HR] 2.0;
= 0.005), multiple HCCs (HR 2.8;
< 0.001), and portal venous invasion (HR 2.3;
= 0.001). LR-HCC was not a prognostic factor. In conclusion, salvage hepatectomy for LR-HCC showed worse surgical outcomes but a favorable prognosis.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37190248</pmid><doi>10.3390/cancers15082320</doi><orcidid>https://orcid.org/0000-0001-9154-246X</orcidid><orcidid>https://orcid.org/0000-0002-6867-228X</orcidid><orcidid>https://orcid.org/0000-0002-2197-9508</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-04, Vol.15 (8), p.2320 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10137253 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Alpha fetoproteins Biomarkers Cancer Care and treatment Chemotherapy Hepatectomy Hepatocellular carcinoma Hepatoma Liver Liver cancer Medical colleges Medical prognosis Methods Patient outcomes Patients Prognosis Serum levels Surgeons Surgery Surgical outcomes Tumors |
| title | Surgical and Oncological Outcomes of Salvage Hepatectomy for Locally Recurrent Hepatocellular Carcinoma after Locoregional Therapy: A Single-Institution Experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T18%3A15%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Surgical%20and%20Oncological%20Outcomes%20of%20Salvage%20Hepatectomy%20for%20Locally%20Recurrent%20Hepatocellular%20Carcinoma%20after%20Locoregional%20Therapy:%20A%20Single-Institution%20Experience&rft.jtitle=Cancers&rft.au=Minagawa,%20Takuya&rft.date=2023-04-16&rft.volume=15&rft.issue=8&rft.spage=2320&rft.pages=2320-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15082320&rft_dat=%3Cgale_pubme%3EA747309029%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2806509737&rft_id=info:pmid/37190248&rft_galeid=A747309029&rfr_iscdi=true |